Last updated: February 12, 2026
Overview
NDC 70954-0017 is a biosimilar product approved by the FDA. Based on publicly available data, it is a biosimilar version of the reference biologic, biosimilar infliximab (Remicade). The product’s market entrance, pricing strategies, and sales potential depend on factors including patent expiry, market competition, reimbursement policies, and manufacturing costs.
Market Landscape
-
Reference Product: Infliximab (Remicade)
Infliximab generated approximately $4.5 billion globally in 2022 (IQVIA). The US contributed roughly $3.5 billion. The drug's primary indications include rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
-
Biosimilar Market Penetration
The biosimilar infliximab entered the U.S. market in 2016. As of 2023, several biosimilars share the market, including CT-P13, SB2, and PF-06438179/GS-4109. Market penetration for biosimilars still varies, with less than 15% of infliximab sales in the U.S. originating from biosimilars but expected to grow.
-
Competitor Products
Biosimilar infliximabs are priced approximately 15-25% below reference biologic prices. Leading biosimilars are priced around $700-$900 per 10 mg/mL vial, compared to the ~$950-$1,100 for the reference.
-
Market Opportunity
The total accessible market for infliximab in the U.S. is approximately $3.5 billion annually. Biosimilar adoption can increase total volume by 10-20%, depending on payer acceptance and physician prescribing patterns.
Pricing Strategy and Projections
-
Initial Launch Price
Based on biosimilar launches, initial prices for NDC 70954-0017 are expected to be approximately 20-25% lower than reference biologic prices. For a typical infusion, initial pricing could be set around $700 per 10 mg/mL vial, considering existing biosimilar benchmarks.
-
Long-term Price Trends
As market share increases and more biosimilars enter, prices may decrease by up to 40-50%. Price erosion is driven by increased competition, payer pressure, and manufacturing efficiencies.
-
Sales Volume Estimates
- Year 1: 10-15% of reference biologic volume (~$350 million U.S. market).
- Year 3-4: Capture 25-30% of the market (~$1 billion in sales), assuming steady market share growth.
-
Reimbursement Dynamics
CMS policies favor biosimilars through better formulary placement and lower reimbursement rates. This incentivizes providers to switch from reference biologics, accelerating uptake.
Price Projections
| Year |
Expected Price per Vial |
Market Share |
Approximate Revenue |
| 2023 |
$700-$750 |
10-15% |
$350-$525 million |
| 2024 |
$650-$700 |
20-25% |
$650-$900 million |
| 2025 |
$600-$650 |
30-35% |
$1 billion+ |
Assumptions are based on current biosimilar pricing trends, competition, and market growth patterns.
Regulatory and Policy Influences
- Patent litigations related to the biologic reference product delay biosimilar market penetration but are expected to settle by 2025.
- CMS and private payer policies increasingly favor biosimilars, supporting further price reductions.
- State laws promoting biosimilar substitutions can accelerate market share.
Risks and Uncertainties
- Payer resistance to lower prices.
- Delays in gaining market share due to physician preferences.
- Potential safety concerns or quality issues impacting uptake.
- Patent disputes prolonging market entry.
Key Takeaways
- NDC 70954-0017 is positioned within a mature biosimilar infliximab market, with initial launch prices around $700 per vial.
- Long-term prices may decline by up to half as competition intensifies.
- Market share could reach 25-30% within 3-4 years, generating revenue exceeding $1 billion annually.
- Regulatory and policy shifts will significantly influence pricing and market penetration.
- The competitive landscape suggests price erosion and increased volume are critical to long-term profitability.
FAQs
1. When is the expected market entry date for NDC 70954-0017?
The product has already received FDA approval; commercial launch should occur within the next 3-12 months, contingent on manufacturing and distribution agreements.
2. What factors could affect the product’s market share?
Physician acceptance, payer reimbursement policies, biosimilar differentiation, patent litigation, and marketing efforts.
3. How does biosimilar pricing compare globally?
European prices are typically 30-50% below reference biologics, with similar trends expected in the U.S., albeit with regional variations.
4. Will price reductions affect profit margins?
Yes; increased competition drives prices down, which can compress margins unless manufacturing efficiencies or volume growth offset lower unit prices.
5. How significant is formulary placement in influencing market uptake?
Critical. Favorable formulary inclusion accelerates adoption, especially when aligned with payer incentives and clinical guidelines.
References:
[1] IQVIA, 2022. Global Oncology Market Data.
[2] FDA. Biosimilar Product Label for Infliximab. 2023.
[3] Center for Medicare & Medicaid Services. Biosimilar Policy Updates. 2023.
[4] EvaluatePharma. Biosimilar Market Trends. 2022.
